ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages

Hughes, 1986, The anticardiolipin syndrome, J. Rheumatol., 13, 486 Harris, 1983, Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus, Lancet., 2, 1211, 10.1016/S0140-6736(83)91267-9 McNeil, 1990, Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H), Proc. Natl. Acad. Sci. USA., 87, 4120, 10.1073/pnas.87.11.4120 Galli, 1990, Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor, Lancet., 335, 1544, 10.1016/0140-6736(90)91374-J Matsuura, 1990, Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease, Lancet., 336, 177, 10.1016/0140-6736(90)91697-9 Matsuura, 1994, Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface, J. Exp. Med., 179, 457, 10.1084/jem.179.2.457 Koike, 1995, Antigenic specificity of the “anticardiolipin” antibodies, Blood., 85, 2277, 10.1182/blood.V85.8.2277.bloodjournal8582277 Igarashi, 1996, Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system, Blood., 87, 3262, 10.1182/blood.V87.8.3262.bloodjournal8783262 Chamley, 1999, Conformationally altered β2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies, Clin. Exp. Immunol., 115, 571, 10.1046/j.1365-2249.1999.00810.x Wang, 2000, Membrane-induced conformational change in human apolipoprotein H, Biochem. J., 348, 103, 10.1042/bj3480103 Roubey, 1995, Anticardiolipin” autoantibodies recognize β2-glycoprotein I structure in the absence of phospholipid. Importance of Ag density and bivalent binding, J. Immunol., 154, 954, 10.4049/jimmunol.154.2.954 Tincani, 1996, The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species' evolution, J. Immunol., 157, 5732, 10.4049/jimmunol.157.12.5732 Sheng, 1998, Anti-β2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to β2-glycoprotein I with low affinity: dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity, J. Immunol, 161, 2038, 10.4049/jimmunol.161.4.2038 Lutters, 2001, Dimers of β2-glycoprotein I mimic the in vitro effects of β2-glycoprotein I-anti-β2-glycoprotein I antibody complexes, J. Biol. Chem., 276, 3060, 10.1074/jbc.M008224200 Wurm, 1984, β2-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles, Int. J. Biochem., 16, 511, 10.1016/0020-711X(84)90168-X Polz, 1988, Isolation of a Specific Lipid-Binding Protein from Human Serum By Affinity Chromatography Using Heparin-Sepharose, 817 Vazquez-Mellado, 1994, Exposure of anionic phospholipids upon platelet activation permits binding of β2-glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects, J. Autoimmun., 7, 335, 10.1006/jaut.1994.1024 Price, 1996, Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner, J. Immunol., 157, 2201, 10.4049/jimmunol.157.5.2201 Bouma, 1999, Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure, EMBO J., 18, 5166, 10.1093/emboj/18.19.5166 Hoshino, 2000, Identification of the phospholipid-binding site of human β2-glycoprotein I domain V by heteronuclear magnetic resonance, J. Mol. Biol., 304, 927, 10.1006/jmbi.2000.4243 Hong, 2001, Flexible loop of β2-glycoprotein I domain V specifically interacts with hydrophobic ligands, Biochemistry., 40, 8092, 10.1021/bi010196v Nakaya, 1980, Activation of human post heparin lipoprotein lipase by apolipoprotein H (β2-glycoprotein I), Biochem. Biophys. Res. Commun., 95, 1168, 10.1016/0006-291X(80)91595-8 Polz, 1979, The binding of β2-glycoprotein-I to human serum lipoproteins. Distribution among density fractions, FEBS Lett., 102, 183, 10.1016/0014-5793(79)80955-2 Polz, 1979, Binding of β2-glycoprotein-I to intralipid: determination of the dissociation constant, Biochem. Biophys. Res. Commun., 90, 1305, 10.1016/0006-291X(79)91178-1 Ross, 1986, The pathogenesis of atherosclerosis-an update, N. Engl. J. Med., 314, 488, 10.1056/NEJM198602203140806 Ross, 1993, The pathogenesis of atherosclerosis: a perspecitive for the 1990s, Nature., 362, 801, 10.1038/362801a0 Palinski, 1989, Low density lipoprotein undergoes oxidative modification in vivo, Proc. Natl. Acad. Sci. USA., 86, 1372, 10.1073/pnas.86.4.1372 Ylä-Herttuala, 1989, Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man, J. Clin. Invest., 84, 1086, 10.1172/JCI114271 Penn, 1994, Oxidized lipoproteins, altered cell function and atherossclerosis, Atherosclerosis., 108, 21, 10.1016/0021-9150(94)90150-3 Steinberg, 1995, Role of oxidized LDL and antioxidants in atherosclerosis, Adv. Exp. Med. Biol., 369, 39, 10.1007/978-1-4615-1957-7_5 Vaarala, 1993, Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus, Lancet., 341, 923, 10.1016/0140-6736(93)91213-6 Tinahones, 1998, Lack of cross reaction between antibodies to β2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome, Br. J. Rheumatol., 37, 746, 10.1093/rheumatology/37.7.746 Romero, 1998, Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-β2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein, Br. J. Rheumatol., 37, 883, 10.1093/rheumatology/37.8.883 Hasunuma, 1997, Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages, Clin. Exp. Immunol., 107, 569, 10.1046/j.1365-2249.1997.00300.x Kobayashi, 2001, A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages, J. Lipid Res., 42, 697, 10.1016/S0022-2275(20)31631-X Matsuura, 1992, Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor, J. Immunol., 148, 3885, 10.4049/jimmunol.148.12.3885 Hashimoto, 1992, Anticardiolipin antibodies in NZW x BXSB FI mice. A model of antiphospholipid syndrome, J. Immunol., 149, 1063, 10.4049/jimmunol.149.3.1063 Ichikawa, 1994, β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome, Arthritis Rheum., 37, 1453, 10.1002/art.1780371008 Havel, 1955, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J. Clin. Invest., 43, 1345, 10.1172/JCI103182 Ohkawa, 1979, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Anal. Biochem., 95, 351, 10.1016/0003-2697(79)90738-3 Folch, 1957, A simple method for the isolation and purification of total lipids from animal tissues, J. Biol. Chem., 226, 497, 10.1016/S0021-9258(18)64849-5 Nishikawa, 1990, Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages, J. Biol. Chem., 265, 5226, 10.1016/S0021-9258(19)34110-9 Kritharides, 1993, A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC, Anal. Biochem., 213, 79, 10.1006/abio.1993.1389 Brown, 1980, The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages, J. Supramol. Struct., 13, 67, 10.1002/jss.400130107 Brown, 1983, Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis, Annu. Rev. Biochem., 52, 223, 10.1146/annurev.bi.52.070183.001255 Heinecke, 1986, Superoxide-mediated modification of low-density lipoprotein by arterial smooth muscle cells, J. Clin. Invest., 77, 757, 10.1172/JCI112371 Parthasarathy, 1990, Oxidative modification of LDL: comparison between cell-mediated and copper-mediated modification, Eur. Heart J., 11 (Suppl. E), 83, 10.1093/eurheartj/11.suppl_E.83 Lamb, 1994, Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein, FEBS Lett., 338, 122, 10.1016/0014-5793(94)80348-X Tribble, 1996, Selective resistance of LDL core lipids to iron-mediated oxidation. Implications for the biological properties of iron-oxidized LDL, Arterioscler. Thromb. Vasc. Biol., 16, 1580, 10.1161/01.ATV.16.12.1580 Kamido, 1995, Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins, J. Lipid Res., 36, 1876, 10.1016/S0022-2275(20)41106-X Hoppe, 1997, Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions, J. Lipid Res., 38, 1347, 10.1016/S0022-2275(20)37418-6 Zhang, 1990, Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages, J. Lipid Res., 31, 1361, 10.1016/S0022-2275(20)42607-0 Bhadra, 1991, Oxidation of cholesterol moiety of low density lipoprotein in the presence of human endothelial cells or Cu2+ ions: identification of major products and their effects, Biochem. Biophys. Res. Commun., 176, 431, 10.1016/0006-291X(91)90942-Z Brown, 1996, Free and esterified oxysterol: formation during copper-oxidation of low density lipoprotein and uptake by macrophages, J. Lipid. Res., 37, 320, 10.1016/S0022-2275(20)37619-7 Cader, 1997, Mechanisms of enhanced macrophage apoE secretion by oxidized LDL, J. Lipid Res., 38, 981, 10.1016/S0022-2275(20)37222-9 Kodama, 1990, Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils, Nature., 343, 531, 10.1038/343531a0 Endemann, 1993, CD36 is a receptor for oxidized low density lipoprotein, J. Biol. Chem., 268, 11811, 10.1016/S0021-9258(19)50272-1 Ramprasad, 1995, The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and PS-rich liposomes is identical to macrosialin, the mouse homologue of human CD68, Proc. Natl. Acad. Sci. USA., 92, 9580, 10.1073/pnas.92.21.9580 Sawamura, 1997, An endothelial receptor for oxidized low-density lipoprotein, Nature., 386, 73, 10.1038/386073a0 Stanton, 1992, A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein, J. Biol. Chem., 267, 22446, 10.1016/S0021-9258(18)41692-4 Lopes-Virella, 1997, The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor, Atherosclerosis., 135, 161, 10.1016/S0021-9150(97)00157-3 Khoo, 1992, Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates, Arterioscler. Thromb., 12, 1258, 10.1161/01.ATV.12.11.1258 Kiener, 1995, Immune complexes of LDL induce atherogenic responses in human monocytic cells, Arterioscler. Thromb. Vasc. Biol., 15, 990, 10.1161/01.ATV.15.7.990 Morganelli, 1995, Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors, J. Lipid Res., 36, 714, 10.1016/S0022-2275(20)40057-4